We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AACC Releases Updated Guidance to Improve Use of POC Tests for Fertility and Reproductive Health

By LabMedica International staff writers
Posted on 05 Sep 2022
Print article
Image: AACC has issued new recommendations for performing POC tests for fertility and reproductive health (Photo courtesy of Pexels)
Image: AACC has issued new recommendations for performing POC tests for fertility and reproductive health (Photo courtesy of Pexels)

Point-of-care tests are clinical tests that are performed near the patient instead of in a central lab. Due to their convenience and rapid turnaround times, these tests can help patients to get treatment much faster than traditional tests. As a result, the use of point-of-care testing has risen steadily in all areas of healthcare. In the fertility and reproductive health fields in particular, it is now used for everything from predicting ovulation and diagnosing pregnancy to managing premature rupture of membranes (PROM) - also known as a patient's water breaking - and high-risk deliveries. However, when point-of-care tests are used inappropriately or performed incorrectly, this can lead to unnecessary follow-up tests and procedures and can even put the patient's health at risk or lead to death.

Now, the American Association for Clinical Chemistry (Washington, DC, USA) has issued a new guidance document with expert recommendations for performing point-of-care tests for fertility and reproductive health. As the use of point-of-care testing rises in these fields, this guidance is intended to ensure that patients and their babies fully benefit from it. AACC has updated guidance that it originally published in 2007 to inform healthcare professionals of the most current best practices for point-of-care testing in reproductive medicine. The highlights of the key recommendations from this document are:

  • Testing for PROM using commercial kits alone is not recommended without clinical signs that a patient's water has broken. Additionally, results from these tests must be interpreted in the context of a patient's clinical presentation to prevent patient harm.
  • Urine luteinizing hormone tests are accurate and reliable predictors of ovulation. These tests can improve the likelihood of conception among healthy fertile women and can also be used to time certain assisted reproduction procedures. However, further study is still needed to determine the efficacy of at-home ovulation prediction kits that use saliva or measure basal body temperature.
  • While blood laboratory pregnancy tests are the gold standard, healthcare providers should consider using pregnancy point-of-care tests in situations where rapid diagnosis of pregnancy is needed for treatment decisions. One such scenario is if a patient presents to the emergency department with unstable vital signs and symptoms indicative of a ruptured ectopic pregnancy that might require surgery.

"Point-of-care testing is growing in popularity as a means of delivering faster turnaround time of test results closer to the patient," said the guidance document authors Drs. James H. Nichols, Mahesheema Ali, John I. Anetor, Li-Sheng Chen, Yu Chen, Sean Collins, Saswati Das, Sridevi Devaraj, Lei Fu, Brad S. Karon, Heba Kary, Robert D. Nerenz, Alex J. Rai, Zahra Shajani-Yi, Vinita Thakur, Sihe Wang, Hoi-Ying Elsie Yu, and Lindsey E. Zamora. "Guidance is needed for optimizing the implementation of [point-of-care testing] in patient care. This guidance document revises previous recommendations and offers best practices for the use of [point-of-care testing] in fertility and reproductive health."

Related Links:
AACC 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bead-Based Multiplex Assay
Human Luminex Discovery Assay
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.